{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:32:32Z","timestamp":1718137952991},"reference-count":9,"publisher":"Informa Healthcare","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1517\/14656566.7.12.1675","type":"journal-article","created":{"date-parts":[[2006,7,28]],"date-time":"2006-07-28T06:50:47Z","timestamp":1154069447000},"page":"1675-1678","source":"Crossref","is-referenced-by-count":3,"title":["Natalizumab in multiple sclerosis: proceed with caution?"],"prefix":"10.1517","volume":"7","author":[{"given":"Sheila A","family":"Doggrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2006,7,28]]},"reference":[{"key":"CIT0001","first-page":"15","volume":"348","author":"MILLER","year":"2003","journal-title":"N"},{"key":"CIT0002","first-page":"899","volume":"354","author":"POLMAN","year":"2006","journal-title":"N"},{"key":"CIT0003","first-page":"375","volume":"353","author":"LANGER-GOULD","year":"2005","journal-title":"N"},{"key":"CIT0004","first-page":"369","volume":"353","author":"KLEINSCHMIDT-DEMASTERS","year":"2005","journal-title":"N"},{"key":"CIT0005","first-page":"911","volume":"354","author":"RUDICK","year":"2006","journal-title":"N"},{"key":"CIT0006","first-page":"362","volume":"353","author":"VAN ASSCHE","year":"2005","journal-title":"N"},{"key":"CIT0007","first-page":"924","volume":"354","author":"YOUSRY","year":"2006","journal-title":"N"},{"key":"CIT0008","first-page":"965","volume":"354","author":"ROPPER","year":"2006","journal-title":"N"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/bmj.332.7538.416","volume":"332","author":"CHAUDHURI","year":"2006","journal-title":"Br. Med. J."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.7.12.1675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T04:00:19Z","timestamp":1497672019000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.7.12.1675"}},"subtitle":["POLMAN CH, O\u2019CONNOR PW, HAVRDOVA E<i>et al.<\/i>: A randomised, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.<i>N. Engl. J. Med.<\/i>(2006)<b>354<\/b>:899-910, RUDICK RA, STUART WH, CALABRESI PA<i>et al.<\/i>: Natalizumab plus interferon-b<sub>1a<\/sub>for relapsing multiple sclerosis.<i>N. Engl. J. Med.<\/i>(2006)<b>354<\/b>:911-923, and YOUSRY TA, MAJOR EO, RYSCHKEWITSCH C<i>et al.<\/i>: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.<i>N. Engl. J. Med.<\/i>(2006)<b>354<\/b>:924-933."],"short-title":[],"issued":{"date-parts":[[2006,7,28]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2006,7,28]]},"published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1517\/14656566.7.12.1675"],"URL":"https:\/\/doi.org\/10.1517\/14656566.7.12.1675","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,28]]}}}